Reportlinker Adds Commercial Insight: Multiple Sclerosis - Next Generation Therapies Signal the Start of a New Era

NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercial Insight: Multiple Sclerosis - Next generation therapies signal the start of a new era

http://www.reportlinker.com/p0243816/Commercial-Insight-Multiple-Sclerosis---Next-generation-therapies-signal-the-start-of-a-new-era.html

Introduction

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).

Scope

*In-depth analysis of the current and future multiple sclerosis therapies across the US, Japan, France, Germany, Italy, Spain and the UK.

*Country-specific total brand sales forecasts for key products, biosimilars and pipeline agents across the seven major markets to 2019.

*Assessment of the commercial opportunities and threats present in the multiple sclerosis market, with analysis of trends in emerging markets.

*Evaluation of the strategies of leading players in the multiple sclerosis disease market.

Highlights

Datamonitor expects Novartis's Gilenia (fingolimod) to launch at the end of 2010 as a first-line therapy, while Merck Serono's oral cladribine is anticipated to launch at the start of 2011. These drugs offer improved efficacy and a less invasive method of administration than current treatments.

Datamonitor expects entry of biosimilar drugs from 2014. The Introduction of cost competition will force current market players to cease raising the price of their drugs above the norm; a strategy that has helped them to substantially increase revenues in recent years.

Novartis is set to usurp Biogen Idec and become the market leading player by the end of the forecast period in 2019. In addition to Gilenia and Extavia (interferon beta 1b), Novartis is developing two multiple sclerosis candidates; PI-230 (Phase I) and BAF312 (Phase II), illustrating its commitment to growing its presence in the marketplace

Reasons to Purchase

*Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats

*Assess key marketed and pipeline drugs, including new oral agents, Acorda's Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).

*Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.

OVERVIEW 1

Catalyst 1

Summary 1

ABOUT DATAMONITOR HEALTHCARE 2

About the central nervous system pharmaceutical analysis team 2

EXECUTIVE SUMMARY 3

Strategic scoping and focus 3

Datamonitor insight into the multiple sclerosis market 3

Related reports 4

TABLE OF CONTENTS 5

1. MARKET DEFINITION 6

Market definition for this report 6

2. MARKET OVERVIEW 7

Seven major markets 7

Current market assessment 7

Notable historical growth in multiple sclerosis sales exceeds volume growth from 2005 to 2009 8

The interferons contributed over half of all sales in the multiple sclerosis disease-modifying market in 2009 10

Copaxone outstrips Avonex to become market leader 11

Approved Tysabri continues strong year-on-year growth 12

Future market assessment 13

Key multiple sclerosis brands will undergo strong competition 13

Market value will continue to grow until generic incursion in 2014 13

Pipeline oral disease modifiers will offset generic incursion 14

Opportunities and threats 17

Opportunities 1: efficacious treatment for progressive multiple sclerosis remains a key unmet need 17

Opportunities 2: identifying patients before symptoms emerge 19

Opportunities 3: development of biomarkers will lead to a earlier treatment approach 20

Opportunities 4: targeting symptomatic treatment opens up large patient population 21

Threat 1: biosimilar competition 24

Threat 2: active cost containment set to dampen growth 27

Threat 3: increasing evidence of lack of efficacy for disease-modifying therapies 28

US 28

Current and future market assessment 28

The US multiple sclerosis market captured the largest share of the seven major markets in 2009 28

The US will continue to be the largest of the seven major markets for multiple sclerosis 29

Opportunities and threats 33

Opportunity 1: first oral drugs awarded Fast Track status 33

Opportunity 2: healthcare reform to open up the market for multiple sclerosis developers 34

Threat 1: drug rebates and discounts offset sales growth 35

Threat 2: further tightening of Pharma marketing practices 35

Japan 36

Current and future market assessment 36

Japan is the smallest of the seven major multiple sclerosis markets 36

Launch of Avonex leads to strong growth in 2007-09 37

Approval of Tysabri and Gilenia will boost market growth 37

Opportunities and threats 40

Opportunity 1: Japanese market has considerable Scope for development 40

Opportunity 2: raising awareness of multiple sclerosis will grow market 40

Opportunity 3: elimination of lengthy approval process provides faster approval times 41

Threat 1: biennial price cuts by the Japanese government 41

Five major EU markets (5EU) 41

Current and future market assessment 41

European multiple sclerosis market sales represent strongest growth of the seven major markets 41

Rebif was the Number 1 European multiple sclerosis brand in 2009 42

Pipeline oral drugs to become multiple sclerosis market leaders 43

Opportunities and threats 46

Opportunity 1: innovative drug development encouraged by price premium and high-level reimbursement 46

Opportunity 2: UK market provides Scope for considerable growth 46

Opportunity 3: more extensive UK training of neurologists and better awareness will promote access to therapies 48

Threat 1: Europe's biosimilar pathway is the most advanced in the seven major markets 48

Threat 2: increase in parallel importation threatens drug prices 49

France 51

Current and future market assessment 51

Historical growth driven by Copaxone and Tysabri 51

France to maintain market value 52

Germany 56

Current and future market assessment 56

German multiple sclerosis market is the strongest growing and largest European country 56

German multiple sclerosis market set to remain the largest and most attractive European country 57

Italy 60

Current and future market assessment 60

Italy showed the lowest CAGR of all the major markets from 2005 to 2009 60

Biosimilars will make less impact in Italy than the rest of the European markets 60

Spain 64

Current and future market assessment 64

Multiple sclerosis market in Spain generated $300m in 2009 64

Strong market growth projected to continue 64

UK 68

Current and future market assessment 68

Despite rapid growth, the UK multiple sclerosis market remains the smallest European market 68

Securing NICE approval remains critical to success of pipeline drugs 69

Rest of the world snapshot 73

Current market assessment 73

Rest of world exhibited stronger CAGR than the US 73

Rest of World growth is slower than the seven major markets 73

Rest of the world only represents 17% of global multiple sclerosis sales 75

Despite its small market size, the BRIC countries demonstrated the strongest growth 76

Copaxone is the leading global drug and demonstrates the strongest growth 77

Opportunities and threats 78

Opportunity 1: increasing awareness and treatment of multiple sclerosis in developing countries 78

Threat 1: cost of premium priced multiple sclerosis therapies will restrict growth 78

3. BRAND DYNAMICS 79

Overview of competitive landscape 79

Oral therapies set to outstrip traditional market leaders 79

Patient acquisition process 80

Introduction 80

Patient care path 80

Points of influence in the patient care path 81

Trigger point 1: assessment of the multiple sclerosis activity severity 81

Trigger point 2: disease duration and activity will influence use of biologics 82

Trigger point 3: location of impairments influences type of rehabilitation 84

Drivers of brand choice 84

Disease-modifying efficacy and safety are the most influential factors in prescription 84

Number one influential factor is disease-modifying efficacy 85

Side effects are second major attribute driving brand choice 85

Compliance dependant on efficacy and side effects 86

Disease modifying therapy cost is high 86

US formulary tier status for leading brands 87

Disease modifying multiple sclerosis drugs are in the highest co-payment tiers 88

Trends in marketing strategies 88

Marketing strategy for leading brands 89

Sponsorship/disease awareness campaigns 90

Marketed brands overview - disease-modifying drugs 91

Avonex (interferon beta-1a; Biogen Idec and Genzyme) - the gold standard 92

Drug profile 92

Datamonitor continues to view Avonex as the gold standard 92

Product positioning 93

Avonex is currently the preferred first choice interferon in multiple sclerosis 93

SWOT analysis 94

Brand forecast to 2019 95

Betaseron (interferon beta-1b; Bayer Schering) 97

Drug profile 97

The first multiple sclerosis disease modifier 97

Product positioning 98

Betaseron benefits from historical experience 98

SWOT analysis 98

Brand forecast to 2019 99

Rebif (interferon beta-1a; Merck Serono and Pfizer) 101

Drug profile 101

Product positioning 101

Rebif has superior efficacy compared to Avonex 101

SWOT analysis 103

Brand forecast to 2019 104

Extavia (interferon beta-1a; Novartis) 106

Drug profile 106

Novartis's branded version of interferon beta-1b 106

Product positioning 106

Extavia will establish the ground for Novartis's multiple sclerosis portfolio 106

SWOT analysis 107

Brand forecast to 2019 108

Copaxone (glatiramer acetate; Teva and Sanofi-Aventis) 110

Drug profile 110

Copaxone is biggest selling multiple sclerosis drug 110

Product positioning 111

First-line therapy in competition against interferons 111

SWOT analysis 112

Brand forecast to 2019 113

Tysabri (natalizumab; Biogen Idec and Elan) 115

Drug profile 115

Sale growth continues despite increase in PML cases 115

Product positioning 116

PML risk hinders Tysabri's movement up the treatment algorithm 116

SWOT analysis 117

Brand forecast to 2019 118

Novantrone (mitoxantrone, Merck Serono); 119

Pipeline brands overview 121

Gilenia (fingolimod, Novartis & Mitsubishi Tanabe Pharma) 122

Drug profile 122

First oral drug expected to enter the multiple sclerosis market 122

Development overview 123

Robust clinical trial program strengthens Gilenia's potential 123

Success will depend on risk-benefit ratio of Gilenia 124

Product positioning 126

Gilenia will compete to become first-line therapy 126

SWOT analysis 126

Drug forecast to 2019 127

Oral cladribine (Merck Serono) 128

Drug profile 128

Refusal to file setback delays launch 128

Development overview 129

Favorable annualized relapse reduction rates compared to interferons 129

Phase III trials show impressive efficacy data 130

Product positioning 131

SWOT analysis 131

Drug forecast to 2019 132

Marketed brands overview - key multiple sclerosis-specific symptomatic drugs 134

Ampyra (dalfampridine; Acorda therapeutics) 135

Drug profile 135

First drug approved to help multiple sclerosis patients walk 135

Product positioning 136

Ampyra would be a useful drug for multiple sclerosis, but payers likely to restrict sales 136

Seizure risk necessitates REMS program 137

SWOT analysis 138

Drug forecast to 2019 138

Sativex (nabiximols; GW Pharmaceuticals) 139

Drug profile 139

Development overview 140

Drug evaluation 142

Drug forecast to 2019 142

4. KEY DEVELOPERS 144

Strategic overview 144

Trends in corporate strategy 145

Licensing deals represent an essential tactic to bolster pipeline agents 145

Recent strategic partnerships and deals 146

Abbott acquire Facet Biotech 146

Novartis 147

Corporate strategy 147

Novartis to become the leading multiple sclerosis developer through Gilenia launch 147

Multiple sclerosis portfolio assessment 147

Biogen Idec 148

Corporate strategy 148

Biogen Idec's will remain a leading multiple sclerosis developer through reformulations and novel candidates 148

Multiple sclerosis portfolio assessment 148

Merck Serono 149

Corporate strategy 149

Multiple sclerosis portfolio assessment 149

Teva 150

Corporate strategy 150

Multiple sclerosis portfolio assessment 150

Portfolio assessment of other leading companies 151

Bayer Schering 151

5. CASE STUDIES 152

Introduction 152

Case study 152

Price increases higher than for other autoimmune disorders 152

Price increases in US the highest across the seven major markets 154

BIBLIOGRAPHY 158

Journal papers 158

Websites 159

Other sources 164

Datamonitor reports 164

APPENDIX A - MARKET ASSUMPTIONS 165

Forecasting assumptions 165

New product launches 165

Patent expiries 165

Data definitions, limitations and assumptions 166

Standard units 166

Country group definitions 166

Rest of European Union 166

Middle East and North Africa (MENA) 166

Rest of World 166

Derivation of sales forecasts and pricing trends 166

Forecast methodology 166

Methodology for symptomatic market forecast 167

APPENDIX B 168

Contributing experts 168

Report methodology 168

About Datamonitor 168

About Datamonitor Healthcare 168

About the Central Nervous System analysis team 169

Disclaimer 171

List of Tables

Table 1: Sales and growth of key multiple sclerosis brands across the seven major markets ($m and %), 2009-19 14

Table 2: Sales forecasts of branded multiple sclerosis drugs across the seven major markets ($m), 2009-19 16

Table 3: Summary of opportunities and threats in the multiple sclerosis market across the seven major markets, 2010-19 17

Table 4: Categorization of multiple sclerosis-related symptoms by severity 22

Table 5: Prevalence and treatment of multiple sclerosis symptoms, 2010 23

Table 6: Sales and growth of key multiple sclerosis brands in the US ($m and %), 2009-19 30

Table 7: Sales forecasts of branded multiple sclerosis drugs in the US ($m), 2009-19 32

Table 8: Summary of opportunities and threats in the multiple sclerosis market in the US, 2010-19 33

Table 9: Sales and growth of key multiple sclerosis brands in Japan ($m and %), 2009-19 38

Table 10: Sales forecasts of branded multiple sclerosis drugs in Japan ($m), 2009-19 39

Table 11: Summary of opportunities and threats in the multiple sclerosis market in Japan, 2010-19 40

Table 12: Sales and growth of key multiple sclerosis brands in the five major EU markets ($m and %), 2009-19 44

Table 13: Sales forecasts of branded multiple sclerosis drugs in the five major EU markets ($m), 2009-19 45

Table 14: Summary of opportunities and threats in the multiple sclerosis market in the five major EU markets, 2010-19 46

Table 15: Sales and growth of key multiple sclerosis brands in France ($m and %), 2009-19 53

Table 16: Sales forecasts of branded multiple sclerosis drugs in France ($m), 2009-19 55

Table 17: Sales and growth of key multiple sclerosis brands in Germany ($m and %), 2009-19 57

Table 18: Sales forecasts of branded multiple sclerosis drugs in Germany ($m), 2009-19 59

Table 19: Sales and growth of key multiple sclerosis brands in Italy ($m and %), 2009-19 61

Table 20: Sales forecasts of branded multiple sclerosis drugs in Italy ($m), 2009-19 63

Table 21: Sales and growth of key multiple sclerosis brands in Spain (Sm and %), 2009-19 65

Table 22: Sales forecasts of branded multiple sclerosis drugs in Spain ($m), 2009-19 67

Table 23: Sales and growth of key multiple sclerosis brands in the UK ($m and %), 2009-19 70

Table 24: Sales forecasts of branded multiple sclerosis drugs in the UK ($m), 2009-19 72

Table 25: Global sales dynamics of the multiple sclerosis market by region ($m), 2005-09 74

Table 26: Sales value of multiple sclerosis brands in the US, five major EU markets and the rest of the world ($m), 2005-09 78

Table 27: Sales of leading multiple sclerosis brands in the seven major markets ($m), 2009-19 79

Table 28: Key products in late-stage R&D pipeline for multiple sclerosis, 2010 80

Table 29: Side effects demonstrated by current multiple sclerosis brands, 2010 86

Table 30: Cost analysis of disease-modifying therapies, based on annual cost per patient ($), 2009 87

Table 31: Representative formulary tier status in the US for leading brands in multiple sclerosis, 2010 88

Table 32: Marketing strategies employed by the companies behind the top three multiple sclerosis market brands, 2010 90

Table 33: Avonex (interferon beta-1a; Biogen Idec and Genzyme) - drug profile, 2010 92

Table 34: Key events and launch dates impacting Avonex's revenue forecasts in the seven major markets, 2010-19 95

Table 35: Betaseron (interferon beta-1b; Bayer Schering) - drug profile, 2010 97

Table 36: Key events and launch dates impacting Betaseron's revenue forecasts in the seven major markets, 2010-19 99

Table 37: Rebif (interferon beta-1a; Merck Serono) - drug profile, 2010 101

Table 38: Key events and launch dates impacting Rebif's revenue forecasts in the seven major markets, 2010-19 104

Table 39: Extavia (interferon beta-1b; Novartis) - drug profile, 2010 106

Table 40: Key events and launch dates impacting Extavia's revenue forecasts in the seven major markets, 2010-19 109

Table 41: Copaxone (glatiramer acetate; Teva and Sanofi-Aventis) - drug profile, 2010 110

Table 42: Key events and launch dates impacting Copaxone's revenue forecasts in the seven major markets, 2010-19 114

Table 43: Tysabri (natalizumab; Biogen Idec and Elan) - drug profile, 2010 115

Table 44: Key events and launch dates impacting Tysabri's revenue forecasts in the seven major markets, 2010-19 118

Table 45: Key late-stage multiple sclerosis disease-modifying drug development pipeline, 2010 122

Table 46: Gilenia (fingolimod; Novartis) - drug profile, 2010 123

Table 47: Key ongoing fingolimod multiple sclerosis studies, 2010 123

Table 48: Key events and launch dates impacting Gilenia's revenue forecast for multiple sclerosis in the seven major markets, 2010-19 127

Table 49: Oral cladribine (Merck Serono)- drug profile, 2010 129

Table 50: Key ongoing oral cladribine multiple sclerosis studies, 2010 130

Table 51: Key events and launch dates impacting oral cladribine's revenue forecast for multiple sclerosis in the seven major markets, 2010-19 133

Table 52: Ampyra (dalfampridine; Acorda therapeutics) - drug profile, 2010 135

Table 53: Sativex (nabiximols; GW Pharmaceuticals)- drug profile, 2010 140

Table 54: Leading companies in the seven major multiple sclerosis markets, 2009-19 144

Table 55: Overview of key players with marketed and pipeline drugs in multiple sclerosis market, 2010 145

Table 56: Summary of licensing partnerships of key therapies, 2010 146

Table 57: Novartis's multiple sclerosis portfolio, 2010 147

Table 58: Biogen Idec's key multiple sclerosis portfolio, 2010 148

Table 59: Merck Serono's multiple sclerosis portfolio, 2010 150

Table 60: Teva's multiple sclerosis portfolio, 2010 150

Table 61: Price ($) per dose for multiple sclerosis disease-modifying drugs across the seven major markets ($/SU)*, 2005-09 152

Table 62: Datamonitor's estimated launch dates for multiple sclerosis products in the US, Japan and 5EU, 2009-19 165

Table 63: Anticipated patent expiry dates for multiple sclerosis brands in the US, Japan and 5EU, 2009-19 165

List of Figures

Figure 1: Timeline: launch dates of disease-modifying therapies for treatment of multiple sclerosis, 1993-2009 8

Figure 2: Multiple sclerosis disease-modifying-specific sales in the seven major markets by region ($ billion), 2005-09 9

Figure 3: Multiple sclerosis disease-modifying specific volume sales in the seven major markets by region ($m), 2005-09 10

Figure 4: Multiple sclerosis disease-modifying drug sales by molecule in the seven major markets ($ billion), 2005-09 11

Figure 5: Performance of the key disease-modifying multiple sclerosis therapies in the seven major markets ($m), 2005-09 12

Figure 6: Key events impacting the multiple sclerosis market, 2010-19 13

Figure 7: Sales forecasts for multiple sclerosis market across the seven major markets ($m), 2009-19 15

Figure 8: Relative proportions of multiple sclerosis subtypes 18

Figure 9: Multiple sclerosis prescription volume and sales split by treatment type across the seven major markets, 2010 24

Figure 10: A global perspective on biosimilars, 2010 26

Figure 11: Multiple sclerosis market sales value in US ($m), 2005-09 29

Figure 12: Sales forecasts for multiple sclerosis market in the US ($m),, 2009-19 30

Figure 13: Multiple sclerosis market sales value in Japan ($m), 2005-09 36

Figure 14: Dynamics of the key multiple sclerosis therapies in Japan, 2006-09 37

Figure 15: Sales forecasts for the multiple sclerosis market in Japan ($m), 2009-19 38

Figure 16: Multiple sclerosis market sales value in the five major EU markets ($m), 2005-09 42

Figure 17: Sales forecasts for multiple sclerosis market in the five major EU markets ($m), 2009-19 43

Figure 18: Biosimilar impact on the multiple sclerosis market in the five major EU markets, 2009-19 49

Figure 19: Impact of parallel importation on the German multiple sclerosis market, 2009 50

Figure 20: Price difference per unit of branded multiple sclerosis drugs compared to parallel import in Germany, 2010 50

Figure 21: Multiple sclerosis market sales value in France ($m), 2005-09 52

Figure 22: Sales forecasts for multiple sclerosis market in France ($m), 2009-19 53

Figure 23: Multiple sclerosis market sales value in Germany ($m), 2005-09 56

Figure 24: Sales forecasts for multiple sclerosis market in Germany ($m), 2009-19 58

Figure 25: Multiple sclerosis market sales value in Italy ($m), 2005-09 60

Figure 26: Sales forecasts for multiple sclerosis market in Italy ($m), 2009-19 62

Figure 27: Multiple sclerosis market sales value in Spain ($m), 2005-09 64

Figure 28: Sales forecasts for multiple sclerosis market in Spain ($m), 2005-09 66

Figure 29: Multiple sclerosis market sales value in the UK ($m), 2005-09 69

Figure 30: Sales forecasts for multiple sclerosis market in the UK ($m), 2009-19 71

Figure 31: Global multiple sclerosis market sales value by region ($ billion), 2005-09 73

Figure 32: Global multiple sclerosis market sales dynamics by major region ($m), 2005-09 75

Figure 33: Global multiple sclerosis market sales volume (IMS standard units sold) and sales value ($) by region, 2009 76

Figure 34: Dynamics of the global multiple sclerosis market sales by region ($m), 2005-09 77

Figure 35: UK multiple sclerosis patient care pathway, 2010 81

Figure 36: Treatment of relapse remitting multiple sclerosis (RRMS), 2010 82

Figure 37: Treatment of secondary progressive multiple sclerosis (SPMS), 2010 83

Figure 38: Treatment of primary progressive multiple sclerosis (PPMS), 2010 83

Figure 39: Treatment of primary relapsing multiple sclerosis (PRMS), 2010 84

Figure 40: Key drivers of brand choice for multiple sclerosis 85

Figure 41: Multiple sclerosis marketing process, 2010 89

Figure 42: Support group websites sponsored and run by Multiple Sclerosis drug developers, 2010 91

Figure 43: Position of Avonex (interferon beta-1a) in the multiple sclerosis treatment algorithm, 2010 94

Figure 44: Avonex (interferon beta-1a; Biogen Idec): SWOT analysis in multiple sclerosis (MS), 2010 95

Figure 45: Avonex (interferon beta-1a; Biogen Idec) sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 96

Figure 46: Position of Betaseron (interferon beta-1b) in the multiple sclerosis treatment algorithm, 2010 98

Figure 47: Betaseron (interferon beta-1b, Bayer Schering): SWOT analysis in multiple sclerosis (MS), 2010 99

Figure 48: Betaseron sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 100

Figure 49: Position of Rebif (interferon beta-1a) in the multiple sclerosis treatment algorithm, 2010 103

Figure 50: Rebif (interferon beta-1a, Merck Serono): SWOT analysis in multiple sclerosis (MS), 2010 104

Figure 51: Rebif sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 105

Figure 52: Position of Extavia (interferon beta 1b) in the multiple sclerosis treatment algorithm, 2010 107

Figure 53: Extavia (interferon beta-1b, Novartis): SWOT analysis in multiple sclerosis (MS), 2010 108

Figure 54: Extavia sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 109

Figure 55: Position of Copaxone (Glatiramer acetate) in the multiple sclerosis (MS) treatment algorithm, 2010 111

Figure 56: Copaxone (glatiramer acetate, Teva and Sanofi Aventis): SWOT analysis in multiple sclerosis (MS), 2010 113

Figure 57: Copaxone sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 114

Figure 58: Position of Tysabri (natalizumab) in the multiple sclerosis treatment algorithm, 2010 116

Figure 59: Tysabri (natalizumab, Biogen Idec and Elan): SWOT analysis in multiple sclerosis (MS), 2010 117

Figure 60: Tysabri sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 119

Figure 61: Position of Novantrone (mitoxantrone) in the multiple sclerosis treatment algorithm, 2010 120

Figure 62: Novantrone sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 121

Figure 63: Gilenia (fingolimod, Novartis): SWOT analysis in multiple sclerosis (MS), 2010 126

Figure 64: Datamonitor's forecast sales for Gilenia across the seven major markets for multiple sclerosis ($m), 2011-19 128

Figure 65: Oral cladribine SWOT analysis, 2010 132

Figure 66: Datamonitor's forecast sales for oral cladribine across the seven major markets for multiple sclerosis ($m), 2011-19 134

Figure 67: Ampyra (dalfampridine; Acorda Therapeutics): SWOT analysis, 2010 138

Figure 68: Datamonitor's forecast sales for Ampyra across the seven major markets for multiple sclerosis ($m), 2010-19 139

Figure 69: Phase III study into Sativex on the relief of spasticity due to multiple sclerosis 141

Figure 70: Datamonitor's forecast sales for Sativex (nabiximols; GW Pharmaceuticals) across the seven major markets for multiple sclerosis ($m), 2010-19 143

Figure 71: Price increases of branded multiple sclerosis disease-modifying therapies across the seven major markets (%), 2005-09 153

Figure 72: Price increases of Copaxone compared to key autoimmune brands across the seven major markets (%), 2005-09 154

Figure 73: Average price increases of branded multiple sclerosis disease-modifying therapies by country (%), 2005-09 155

Figure 74: Estimated US sales revenue if drug developers had increased prices in line with inflation compared to historical sales ($m), 2005-09 156

To order this report:

Therapy Industry: Commercial Insight: Multiple Sclerosis - Next generation therapies signal the start of a new era

Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.